Abstract
Receptor tyrosine kinases, mediators of a variety of critical cellular functions, contribute to tumor progression and metastasis. The epidermal growth factor receptor (EGFR), a member of the receptor tyrosine kinase family, is ubiquitously expressed on the surface of mammalian cells. Erlotinib hydrochloride (Tarceva) can inhibit the intracellular phosphorylation of tyrosine kinases. To investigate the influence of dosing time on the ability of erlotinib to inhibit tumor growth and the underlying molecular mechanisms via the PI3K/AKT and ERK/MAPK pathway, we established nude mice HCC827 tumor xenografts models. The tumor-bearing mice were housed 3-4 per cage under standardized light/dark cycle conditions (lights on at 07:00 h, off at 19:00 h) with food and water ad libitum. The mice were randomly divided into erlotinib treated groups and control groups, gavaged with erlotinib and vehicle respectively at 6 different time points for 21 days. To draw tumor growth curves, the tumor volume was measured every three days. After the mice were sacrificed, the tumor masses of each group were removed and weighed. The relative protein expression levels of p-EGFR, p-AKT and p-MAPK were assayed at 4 h after erlotinib or vehicle gavage by West...Continue Reading
References
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Aug 12, 2003·Cancer·Bruno VincenziGiuseppe Tonini
Mar 5, 2004·Expert Opinion on Therapeutic Targets·Jeffrey Sprouse
May 1, 2004·Science·J Guillermo PaezMatthew Meyerson
May 5, 2004·Seminars in Oncology·Wade Smith, Fadlo R Khuri
Jul 31, 2004·Science·Raffaella SordellaJeffrey Settleman
Oct 20, 2004·Cancer Research·Sean TracyPasi A Jänne
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Thomas FriessMax Hasmann
Mar 25, 2006·International Journal of Cancer. Journal International Du Cancer·Niels ReinmuthMichael Thomas
Apr 6, 2006·Cancer Causes & Control : CCC·Francis Lévi
May 30, 2006·Cancer Cell·Hongbin JiKwok-Kin Wong
Nov 22, 2007·Cancer Chemotherapy and Pharmacology·Laura K ZerbeAlvin M Malkinson
Feb 19, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alba A BrandesRoger Stupp
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Jan 26, 2010·Carcinogenesis·Zhenfeng ZhangBalazs Halmos
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L CrinòUNKNOWN ESMO Guidelines Working Group
Feb 26, 2011·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayDonald Maxwell Parkin
Mar 14, 2013·Bioorganic & Medicinal Chemistry Letters·Kristine Griffett, Thomas P Burris
Sep 24, 2013·Clinical Therapeutics·John R Goffin, Kevin Zbuk
Feb 4, 2014·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Haruhisa KitanoStephen M Hewitt
Jul 17, 2014·Cancer Treatment Reviews·Solange PetersAlex A Adjei
Oct 4, 2014·Nature Communications·Mattia LauriolaYosef Yarden
Nov 20, 2014·BMC Cancer·Yongjun GuoJihong Zhang
Citations
Apr 14, 2016·Trends in Molecular Medicine·Robert DallmannFrancis Lévi
Oct 19, 2017·International Journal of Molecular Sciences·Narin OzturkAlper Okyar
Mar 3, 2020·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Danyi LuBaojian Wu
Apr 17, 2020·Cancers·Müge YalçinAngela Relógio
Oct 30, 2020·Cancers·Janina HesseAngela Relógio
Feb 23, 2018·Biochemical and Biophysical Research Communications·Takashi MatsunagaShigehiro Ohdo